Anti-Mouse CD28 Antibody Reference: HY-P99123 Anti-Mouse CD28 Antibody is an anti-mouse CD28 IgG antibody inhibitor derived from the host Syrian Hamster.
Anti-Mouse 4-1BB Antibody Reference: HY-P99119 Anti-Mouse 4-1BB Antibody is an anti-mouse 4-1BB IgG2a antibody inhibitor derived from the host Rat.
Opucolimab Reference: HY-P99785 Opucolimab is an anti-PD-L1 recombinant human monoclonal antibody. Opucolimab can be used to synthesis antibody agent conjugates. Opucolimab can be used for the research of advanced solid tumors.
Anti-Mouse CD8 beta Antibody Reference: HY-P99128 Anti-Mouse CD8 beta Antibody is an anti-mouse CD8 beta IgG1 antibody inhibitor derived from host Rat.
Anti-Mouse PD-1 Antibody Reference: HY-P99144 Anti-Mouse PD-1 Antibody is an anti-mouse PD-1 IgG1 antibody inhibitor.
Ixekizumab Reference: HY-P9924 Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A (KD<3 pM). Ixekizumab directly blocks IL-17A binding to IL-17RA (IL-17A receptor) but does not bind to other IL-17 family members. Ixekizumab is used for the research of moderate-to-severe plaque psoriasis.
Trastuzumab Reference: HY-P9907 Trastuzumab is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.
Felzartamab Reference: HY-P99616 Felzartamab (MOR-202) is a human monoclonal antibody that targets CD38 and can be used in multiple myeloma research.
Daratumumab Reference: HY-P9915 Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition.
Azintuxizumab Reference: HY-P99453 Azintuxizumab is a monoclonal, B-cell maturation antigen (BCMA)-targeted, IgG4 bispecific antibody. Azintuxizumab has the potential for the research of relapsed/refractory multiple myeloma (RRMM).
Carlumab Reference: HY-P99188 Carlumab (CNTO 888) is a humanised anti-CCL2 (chemokine ligand 2) antibody with high affinity. Carlumab can be used in cancer research, particularly in prostate cancer.
Certolizumab pegol Reference: HY-P9953 Certolizumab pegol (Certolizumab) is a recombinant, polyethylene glycolylated, antigen-binding fragment of a humanized monoclonal antibody that selectively targets and neutralizes tumour necrosis factor-α (TNF-α). Certolizumab pegol can be used for rheumatoid arthritis and Crohn disease research.